European journal of internal medicine · 2026
Pharmacokinetic robustness of direct oral anticoagulants vs. phenprocoumon in the emergency setting: impact of renal and hepatic impairment.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Merzou Fatma, Tarantini Luca, Landau Benjamin, Lesmeister Martin, Martin Hanna, Bertsch Thomas, Mathur Shrey, Groppa Sergiu, Winter Yaroslav, Fassbender Klaus, Lochner Piergiorgio
Аннотация
BACKGROUND: Direct oral anticoagulants (DOACs) are increasingly used, but their pharmacokinetic stability compared to vitamin K antagonists during acute illness remains poorly characterized. We aimed to evaluate the impact of renal and hepatic dysfunction on anticoagulant levels in patients presenting to the emergency department.
METHODS: This multi-center cohort study included 608 patients on established treatment with rivaroxaban, apixaban, dabigatran, edoxaban, or phenprocoumon. Above-threshold anticoagulant levels were determined via drug-specific plasma concentrations, anti-Xa activity, Hemoclot assays, or INR. Multivariable regression was used to assess the impact of renal function and the Model for End-Stage Liver Disease (MELD) score on supratherapeutic levels.
RESULTS: Of 608 patients, 457 (75%) received DOACs and 151 (25%) phenprocoumon. Supratherapeutic levels were significantly less frequent with apixaban (14.4%; OR 0.41, 95% CI 0.25-0.69) and edoxaban (10.8%; OR 0.30, 95% CI 0.10-0.90) compared to phenprocoumon (28.5%). Impaired renal function was independently associated with above-threshold levels for DOACs (OR 1.55, 95% CI 1.17-2.05)-particularly apixaban (OR 2.23, 95% CI 1.33-3.75)-but not for phenprocoumon (OR 1.18, 95% CI 0.79-1.76). Conversely, hepatic dysfunction (MELD score) significantly increased the probability of above-threshold levels (OR 3.80, 95% CI 2.78-5.21), with a more pronounced effect on phenprocoumon (OR 5.26, 95% CI 2.86-9.68) than DOACs (OR 3.46, 95% CI 2.44-4.92).
CONCLUSIONS: DOACs demonstrate superior pharmacokinetic robustness compared to phenprocoumon in the emergency setting. However, DOAC levels are highly sensitive to renal fluctuations, whereas phenprocoumon is more susceptible to hepatic impairment. These findings suggest that individualized monitoring may be necessary for DOAC patients with acute renal decline.
METHODS: This multi-center cohort study included 608 patients on established treatment with rivaroxaban, apixaban, dabigatran, edoxaban, or phenprocoumon. Above-threshold anticoagulant levels were determined via drug-specific plasma concentrations, anti-Xa activity, Hemoclot assays, or INR. Multivariable regression was used to assess the impact of renal function and the Model for End-Stage Liver Disease (MELD) score on supratherapeutic levels.
RESULTS: Of 608 patients, 457 (75%) received DOACs and 151 (25%) phenprocoumon. Supratherapeutic levels were significantly less frequent with apixaban (14.4%; OR 0.41, 95% CI 0.25-0.69) and edoxaban (10.8%; OR 0.30, 95% CI 0.10-0.90) compared to phenprocoumon (28.5%). Impaired renal function was independently associated with above-threshold levels for DOACs (OR 1.55, 95% CI 1.17-2.05)-particularly apixaban (OR 2.23, 95% CI 1.33-3.75)-but not for phenprocoumon (OR 1.18, 95% CI 0.79-1.76). Conversely, hepatic dysfunction (MELD score) significantly increased the probability of above-threshold levels (OR 3.80, 95% CI 2.78-5.21), with a more pronounced effect on phenprocoumon (OR 5.26, 95% CI 2.86-9.68) than DOACs (OR 3.46, 95% CI 2.44-4.92).
CONCLUSIONS: DOACs demonstrate superior pharmacokinetic robustness compared to phenprocoumon in the emergency setting. However, DOAC levels are highly sensitive to renal fluctuations, whereas phenprocoumon is more susceptible to hepatic impairment. These findings suggest that individualized monitoring may be necessary for DOAC patients with acute renal decline.